Microchip Bio's new indication for Chidamide was approved for marketing in Japan

On December 1, Chipchip announced that the company’s partner, Huya Bio, has recently received approval from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) to approve the listing of Chidamide (Overseas No.

Chidamide is a new molecular entity drug exclusively discovered by Chipchip, the world's first subtype-selective histone deacetylase (HDAC) inhibitor and the world's first approved treatment for peripheral T-cell lymphoma and combined endocrine therapy Oral drugs for drug treatment of patients with estrogen receptor-positive breast cancer belong to the class of epigenetic modulators

In June 2021, Chidamide for monotherapy in the treatment of relapsed or refractory (R/R) adult T-cell leukemia (ATL) was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA)

Peripheral T-cell lymphomas (PTCLs) are a group of highly heterogeneous lymphocytic abnormal malignant proliferative diseases, belonging to non-Hodgkin lymphomas, including mature T-cell and NK-cell tumors of thymic origin

After Chidamide is approved in Japan this time, Huya will be able to commercialize Chidamide, and Microchip Bio will receive the corresponding milestone revenue and a corresponding proportion of future sales